|
Palo Alto, CA, August 28, 2003 — Telik, Inc. (Nasdaq:
TELK) announced that Michael M. Wick, M.D., Ph.D., chairman and
chief executive officer, will present a company update at the Thomas
Weisel Partners Healthcare Tailwinds 2003 Conference in Boston on
September 4, 2003 at 10:35 a.m. Eastern time (7:35 a.m. Pacific
time). A live webcast of the presentation will be accessible at
Telik’s website, www.telik.com. An archive of the webcast
will be available on the Telik website through September 12, 2003.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company working
to discover, develop and commercialize small molecule drugs to treat
serious diseases for which there is significant demand for new therapies.
The company’s most advanced drug development candidate is
TELCYTA™ (TLK286), in a Phase 3 registration trial in advanced
ovarian cancer and in earlier stage clinical trials in ovarian,
non-small cell lung and breast cancer. TLK199 is in a Phase 1-2a
trial in myelodysplastic syndrome, a form of pre-leukemia. Telik’s
product candidates were discovered using its proprietary drug discovery
technology, TRAP, which enables the rapid and efficient discovery
of small molecule drug candidates. Additional information is available
at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2003
Press Releases2004
Press ReleasesEvents
|
